Cart
sales@molnova.com
Vodobatinib
CAS No. 1388803-90-4
Vodobatinib( K-0706 )
Catalog No. M23547 CAS No. 1388803-90-4
Vodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 75 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 212 | In Stock |
|
| 50MG | 333 | In Stock |
|
| 100MG | 517 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1249 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVodobatinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionVodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
-
DescriptionVodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
-
In VitroIn Ba/F3 cells expressing BCR-ABL1, BCR-ABL1L248V, BCR-ABL1Y253H, or BCR-ABL1E255V, Vodobatinib (K0706; 0-2000 nM) treatment shows potent inhibition of BCR-ABL1 tyrosine autophosphorylation.
-
In Vivo——
-
SynonymsK-0706
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorBCR-ABL1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1388803-90-4
-
Formula Weight453.92
-
Molecular FormulaC27H20ClN3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
N-Desmethyl imatinib
N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
-
AN-019
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
-
WP1130
WP1130 (Degrasyn) is a small molecule that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression (IC50=1.8 uM).
